Add to Favourites
To login click here
A new publication in the May issue of Nature Aging by researchers from Integrated Biosciences demonstrates the power of artificial intelligence (AI) to discover novel senolytic compounds, a class of small molecules under intense study for their ability to suppress age-related processes such as fibrosis, inflammation and cancer. The paper describes the AI-guided screening of more than 800,000 compounds to reveal three drug candidates with comparable efficacy and superior medicinal chemistry properties than those of senolytics currently under investigation. This research result is a significant milestone for both longevity research and the application of artificial intelligence to drug discovery.